Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction

NCT05577819 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05577819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05577819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
October 2, 2020
Completion date
December 31, 2026
Enrollment
515 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, heart failure, heart failure, diastolic, transthyretin amyloidosis